Imugene Limited

ASX:IMU ISIN:AU000000IMU9

Imugene Limited ASX IMUImugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

 
    
        

Lihat di Bahasa Lain

Berita

Laporan Pasar Australia 16 September 2010: Conquest Mining Limited (ASX:CQT) memulai Kontrak Pengambilan Emas-Perak-Tembaga dengan Shandong Guoda Gold

🕔9/16/2010 1:30:08 PM 15124

Laporan Pasar Australia 16 September 2010 memuat; Conquest Mining Limited (ASX:CQT) telah memulai kontrak pengambilan kandungan untuk penjualan kandungan emas-perak dan tembaga dari cadangan V2 pada Proyek Mt Carlton,Heemskirk Consolidated Limited (ASX:HSK) telah mengumumkan penanda tanganan persetujuan dengan Conquest Mining Limited (ASX:CQT), Imugene Limited (ASX:IMU) hari ini telah mengumumkan bahwa mereka telah berhasil menyelesaikan uji coba kedua untuk Vaksin Porcine Reproductive and Respiratory Syndrome (PRRS) dan Synthesis Energy Systems Inc. (NASDAQ:SYMX) dan Coalworks Limited (ASX:CWK) hari ini menampilkan presentasi bersama yang bertema “Produksi Bahan Bakar Cair dari Oaklands Coal Utilizing U-GAS (R) dan MTG Technologies”.

Baca Full Story
###

79,864 TAMPILAN PROFIL PERUSAHAAN

  • Halaman ini dilihat: (7 Hari Terakhir: 14) (30 Hari Terakhir: 47) (Sejak Ditampilkan: 7940) 

Data Perusahaan

    Markas Besar
  • Suite 1, 1233 High Street
    Armadale, VIC 3143
    Australia
  • Telepon
  • +61-3-9824-5254 
  • Fax
  • +61-3-9822-7735 
  • Sektor Utama
  • Kesehatan & Pharm 
  • Industri Utama
  • Biotechnology 
  • Homepage
  • www.imugene.com

Lebih banyak Berita lagi

  • 2024/11/20: Updated Appendix 3Z*
  • 2024/11/20: Final Director's Interest Notice*
  • 2024/11/15: Director Resignation*
  • 2024/11/14: Imugene 2024 AGM Results*
  • 2024/11/14: Imugene AGM Presentation*
  • 2024/11/11: onCARlytics Trial Doses First Patient in IT Combination Arm*
  • 2024/11/08: Imugene Opens First Australian Site for azer-cel Trial*
  • 2024/11/05: Complete Response in MAST Study Maintained Over Two Years*
  • 2024/10/31: Quarterly Activities/Appendix 4C Cash Flow Report*
  • 2024/10/14: Notification regarding unquoted securities - IMU*
*refer to company website

Media sosial